AR124395A1 - Agonistas del receptor del polipéptido tipo glucagón 1 (glp-1) de acción prolongada y métodos de uso de los mismos - Google Patents
Agonistas del receptor del polipéptido tipo glucagón 1 (glp-1) de acción prolongada y métodos de uso de los mismosInfo
- Publication number
- AR124395A1 AR124395A1 ARP210103539A ARP210103539A AR124395A1 AR 124395 A1 AR124395 A1 AR 124395A1 AR P210103539 A ARP210103539 A AR P210103539A AR P210103539 A ARP210103539 A AR P210103539A AR 124395 A1 AR124395 A1 AR 124395A1
- Authority
- AR
- Argentina
- Prior art keywords
- glp
- methods
- receptor agonist
- long
- disclosed
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 abstract 4
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 abstract 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 4
- 208000030159 metabolic disease Diseases 0.000 abstract 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 101000788682 Homo sapiens GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 208000016097 disease of metabolism Diseases 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Polipéptidos aislados que son análogos de acción prolongada del GLP-1 humano. Los polipéptidos agonistas del receptor de GLP-1 divulgados tienen propiedades fisicoquímicas beneficiosas con relación al GLP-1 conocido y los polipéptidos agonistas del receptor de GLP-1 sintéticos conocidos, tal como una vida media (t₁/₂) de eliminación más prolongada (es decir, de acción prolongada) y una solubilidad y estabilidad térmica mejoradas. Esta invención también se relaciona con métodos para usar los polipéptidos agonistas del receptor de GLP-1 divulgados en la presente en una variedad de indicaciones terapéuticas, así como con métodos para producir los mismos. Los polipéptidos agonistas del receptor de GLP-1 divulgados son de particular utilidad en métodos de tratamiento de enfermedades o trastornos metabólicos, tal como diabetes tipo 2, para tratar la obesidad y para proveer pérdida de peso, y en métodos de tratamiento de la enfermedad de hígado graso no alcohólico (NAFLD) y/o esteatohepatitis no alcohólica (NASH).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063126736P | 2020-12-17 | 2020-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124395A1 true AR124395A1 (es) | 2023-03-22 |
Family
ID=80123475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103539A AR124395A1 (es) | 2020-12-17 | 2021-12-16 | Agonistas del receptor del polipéptido tipo glucagón 1 (glp-1) de acción prolongada y métodos de uso de los mismos |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12084485B2 (es) |
| EP (1) | EP4263587A1 (es) |
| JP (1) | JP2024502740A (es) |
| KR (1) | KR20230156689A (es) |
| CN (1) | CN116917311A (es) |
| AR (1) | AR124395A1 (es) |
| AU (1) | AU2021400738A1 (es) |
| CA (1) | CA3202389A1 (es) |
| IL (1) | IL303686A (es) |
| MX (1) | MX2023007224A (es) |
| TW (1) | TW202237628A (es) |
| WO (1) | WO2022133148A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| KR102873595B1 (ko) | 2021-09-15 | 2025-10-22 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 장애의 치료를 위한 조성물 및 방법 |
| GB2641696A (en) * | 2023-02-10 | 2025-12-10 | Hangzhou Sciwind Biosciences Co Ltd | Polypeptide and derivative thereof, composition, and use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010538069A (ja) * | 2007-09-07 | 2010-12-09 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | エキセンディン−４およびエキセンディン−３の類似体 |
| KR102093612B1 (ko) | 2009-09-28 | 2020-03-26 | 인타르시아 세라퓨틱스 인코포레이티드 | 실질 항정상태 약물 전달의 신속 확립 및/또는 종결 |
| US9163227B2 (en) * | 2011-12-22 | 2015-10-20 | Covx Technologies Ireland Limited | Anti-diabetic compounds |
| UA116217C2 (uk) * | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| RU2760007C2 (ru) * | 2016-05-16 | 2021-11-22 | Интарсия Терапьютикс, Инк. | Полипептиды, селективные к рецепторам глюкагона, и способы их применения |
| CN111333714A (zh) * | 2020-03-05 | 2020-06-26 | 成都奥达生物科技有限公司 | 一种长效glp-1化合物 |
-
2021
- 2021-12-16 US US17/553,381 patent/US12084485B2/en active Active
- 2021-12-16 CA CA3202389A patent/CA3202389A1/en active Pending
- 2021-12-16 KR KR1020237023789A patent/KR20230156689A/ko active Pending
- 2021-12-16 IL IL303686A patent/IL303686A/en unknown
- 2021-12-16 AU AU2021400738A patent/AU2021400738A1/en active Pending
- 2021-12-16 CN CN202180089098.0A patent/CN116917311A/zh active Pending
- 2021-12-16 AR ARP210103539A patent/AR124395A1/es unknown
- 2021-12-16 WO PCT/US2021/063920 patent/WO2022133148A1/en not_active Ceased
- 2021-12-16 JP JP2023537184A patent/JP2024502740A/ja active Pending
- 2021-12-16 EP EP21851897.5A patent/EP4263587A1/en active Pending
- 2021-12-16 MX MX2023007224A patent/MX2023007224A/es unknown
- 2021-12-17 TW TW110147341A patent/TW202237628A/zh unknown
-
2024
- 2024-07-22 US US18/779,857 patent/US20250034225A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021400738A1 (en) | 2023-07-13 |
| US12084485B2 (en) | 2024-09-10 |
| EP4263587A1 (en) | 2023-10-25 |
| US20250034225A1 (en) | 2025-01-30 |
| WO2022133148A1 (en) | 2022-06-23 |
| TW202237628A (zh) | 2022-10-01 |
| MX2023007224A (es) | 2023-09-05 |
| CN116917311A (zh) | 2023-10-20 |
| IL303686A (en) | 2023-08-01 |
| US20230063420A1 (en) | 2023-03-02 |
| CA3202389A1 (en) | 2022-06-23 |
| JP2024502740A (ja) | 2024-01-23 |
| KR20230156689A (ko) | 2023-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124395A1 (es) | Agonistas del receptor del polipéptido tipo glucagón 1 (glp-1) de acción prolongada y métodos de uso de los mismos | |
| ES2748038T3 (es) | Composiciones, usos y métodos para el tratamiento de trastornos y enfermedades metabólicos | |
| PH12017500761A1 (en) | Co-agonists of glucagon and glp-1 receptors | |
| PE20220965A1 (es) | Analogos de relaxina y metodos para usarlos | |
| UY26974A1 (es) | Agonistas del receptor beta3 adrenérgico y usos de los mismos | |
| AR069136A1 (es) | Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 (peptido somilar al glucagon tipo 1) y usos de los mismos | |
| CO6561836A2 (es) | Polipeptidos agonistas que se enlazan a dr5 | |
| BR112022023834A2 (pt) | Composto duplo-agonista para os receptores de glp-1 e gip e aplicação do mesmo | |
| BR112015001451B1 (pt) | Composto, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, utilização de um composto ou de seu sal ou solvato farmaceuticamente aceitável | |
| PE20170954A1 (es) | Compuestos co-agonistas de gip y glp-1 | |
| AR076147A1 (es) | Fusiones y conjugados de farmaco. composicion farmaceutica. uso. procedimiento. | |
| RU2011129784A (ru) | Основанные на амидах пролекарства пептидов глюкагонового надсемейства | |
| CL2020002718A1 (es) | Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos. | |
| RU2012136450A (ru) | Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения | |
| EA201171197A8 (ru) | Замещенные производные азоантрацена, фармацевтические композиции и способы их применения | |
| SV2008002511A (es) | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos | |
| CA2555894A1 (en) | Pancreatic polypeptide family motifs and polypeptides comprising the same | |
| AR059982A1 (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
| BRPI0412986A (pt) | composto, método para o diagnóstico ou formação de imagem in vivo de uma doença ou condição associadas com a angiogênese, formulação radiofarmacêutica, método para a preparação de um composto, e, kit para a preparação de um peptìdeo radiofluorado | |
| CO6280539A2 (es) | Agonistas mezclados, basados en gip para el tratamiento de trastornos metabolicos y obesidad | |
| AR076973A1 (es) | Composicion tensioactiva reconstituida mejorada que contiene analogos de la proteina tensioactiva b (sp-b) y de la proteina tensioactiva c (sp-c) | |
| AR099976A1 (es) | Agonistas peptídicos duales de los receptores de glp-1 / glucagón derivados de la exendina-4 | |
| ES2925102T3 (es) | Nuevo derivado de arileteno y composición farmacéutica que lo contiene como ingrediente activo | |
| CL2008003197A1 (es) | Anticuerpo que se une especificamente a la region n-terminal del peptido alfa-beta8-x; hibridoma y proceso de preparacion del anticuerpo; metodo para detectar la carga amiloide in vitro en un mamifero; kit, composicion terapeutica y de vacuna que comprenden al anticuerpo; uso del anticuerpo para tratar la enfermedad de alzheimer. | |
| MX2021004185A (es) | Polipeptidos analogos de la amilina humana y sus metodos de uso. |